How I treat splanchnic vein thrombosis

Blood

Volumn 124, Issue 25, 2014, Pages 3685-3691

  Ageno, Walter ^a   Dentali, Francesco ^a   Squizzato, Alessandro ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; PROPRANOLOL; VASODILATOR AGENT; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; HUMAN; LONG TERM CARE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; SPLANCHNIC VEIN THROMBOSIS; VEIN THROMBOSIS; AGED; CASE REPORT; DRUG EFFECTS; FEMALE; MALE; MESENTERIC VEIN; MIDDLE AGED; PATHOLOGY; PORTAL VEIN; RISK FACTOR; SPLANCHNIC BLOOD FLOW; SPLENIC VEIN; TREATMENT OUTCOME; VENOUS THROMBOSIS;

AGED; ANTICOAGULANTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MESENTERIC VEINS; MIDDLE AGED; PORTAL VEIN; PRACTICE GUIDELINES AS TOPIC; PROPRANOLOL; RISK FACTORS; SPLANCHNIC CIRCULATION; SPLENIC VEIN; TREATMENT OUTCOME; VASODILATOR AGENTS; VENOUS THROMBOSIS; WARFARIN;

EID: 84919673916     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-551515     Document Type: Article

References (41)

1. Rajani R, Melin T, Björnsson E, et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience. Liver Int. 2009;29(2):253-259.
2. Rajani R, Björnsson E, Bergquist A, et al. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther. 2010;32(9):1154-1162.
3. Acosta S, Alhadad A, Svensson P, Ekberg O. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg. 2008;95(10):1245-1251.
4. Ageno W, Squizzato A, Togna A, et al. Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study. J Thromb Haemost. 2012;10(1):158-160.
5. Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol. 2010;8(2):200-205.
6. Ageno W, Riva N, Schulman S, et al; IRSVT study group. Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost. 2014;40(1):99-105.
7. Darwish Murad S, Plessier A, Hernandez-Guerra M, et al; EN-Vie (European Network for Vascular Disorders of the Liver). Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151(3):167-175.
8. Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Phmyeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009;113(22):5617-5623.
9. Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HLA, Leebeek FWG. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012; 120(25):4921-4928.
10. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985-4996, quiz 5105.
11. Parker C, Omine M, Richards S, et al; International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699-3709.
12. Shetty S, Ghosh K. Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis - a concise review. Thromb Res. 2011;127(6):505-512.
13. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. A meta-analysis. Thromb Haemost. 2008;99(4):675-682.
14. De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med. 2010;5(6):487-494.
15. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC; European Group for the Study of Vascular Disorders of the Liver. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38(3):364-371.
16. Senzolo M, Cholongitas EC, Patch D, Burroughs AK. Update on the classification, assessment of prognosis and therapy of Budd-Chiari syndrome. Nat Clin Pract Gastroenterol Hepatol. 2005;2(4): 182-190.
17. Darwish Murad S, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology. 2004;39(2): 500-508.
18. Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres. J Hepatol. 2006;44(3):520-528.
19. Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology. 2000;32(3):466-470.
20. Cohen J, Edelman RR, Chopra S. Portal vein thrombosis: a review. Am J Med. 1992;92(2): 173-182.
21. Condat B, Valla D. Nonmalignant portal vein thrombosis in adults. Nat Clin Pract Gastroenterol Hepatol. 2006;3(9):505-515.
22. Mínguez B, García-Pagán JC, Bosch J, et al. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology. 2006;43(4):707-714.
23. Dhiman RK, Puri P, Chawla Y, et al. Biliary changes in extrahepatic portal venous obstruction: compression by collaterals or ischemic? Gastrointest Endosc. 1999;50(5): 646-652.
24. Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345(23): 1683-1688.
25. Grendell JH, Ockner RK. Mesenteric venous thrombosis. Gastroenterology. 1982;82(2): 358-372.
26. Kamath PS. Budd-Chiari syndrome: Radiologic findings. Liver Transpl. 2006;12(11 Suppl 2): S21-S22.
27. Tessler FN, Gehring BJ, Gomes AS, et al. Diagnosis of portal vein thrombosis: value of color Doppler imaging. AJR Am J Roentgenol. 1991; 157(2):293-296.
28. Bradbury MS, Kavanagh PV, Chen MY, Weber TM, Bechtold RE. Noninvasive assessment of portomesenteric venous thrombosis: current concepts and imaging strategies. J Comput Assist Tomogr. 2002;26(3):392-404.
29. Chou CK, Mak CW, Tzeng WS, Chang JM. CT of small bowel ischemia. Abdom Imaging. 2004;29(1):18-22.
30. Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001;120(2):490-497.
31. Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al; European Network for Vascular Disorders of the Liver (EN-Vie). Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51(1):210-218.
32. Spaander MCW, Hoekstra J, Hansen BE, Van Buuren HR, Leebeek FW, Janssen HLA. Anticoagulant therapy in patients with noncirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost. 2013;11(3):452-459.
33. Hedayati N, Riha GM, Kougias P, et al. Prognostic factors and treatment outcome in mesenteric vein thrombosis. Vasc Endovascular Surg. 2008;42(3):217-224.
34. Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology.1999;30(1):84-89.
35. Amitrano L, Guardascione MA, Scaglione M, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol. 2007;102(11):2464-2470.
36. Senzolo M, M Sartori T, Rossetto V, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int. 2012;32(6):919-927.
37. Dentali F, Ageno W, Witt D, et al; WARPED consortium. Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. Thromb Haemost. 2009;102(3):501-504.
38. Kearon C, Akl EA, Comerota AJ, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e419S-94S.
39. DeLeve LD, Valla DC, Garcia-Tsao G; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology. 2009; 49(5):1729-1764.
40. Pannach S, Babatz J, Beyer-Westendorf J. Successful treatment of acute portal vein thrombosis with rivaroxaban. Thromb Haemost. 2013;110(4):626-627.
41. Martinez M, Tandra A, Vuppalanchi R. Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology. 2014;60(1):425-426.